| Mrs Sarah Elyse Meyers, MA,CCC-SLP | |
|
7100 N High St, 203, Worthington, OH 43085-2316 | |
| (614) 505-7330 | |
| (614) 388-5808 |
| Full Name | Mrs Sarah Elyse Meyers |
|---|---|
| Gender | Female |
| Speciality | Speech-language Pathologist |
| Location | 7100 N High St, Worthington, Ohio |
| Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1174886410 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 235Z00000X | Speech-language Pathologist | 9468 (Ohio) | Primary |
| Mailing Address | Practice Location Address |
|---|---|
| Mrs Sarah Elyse Meyers, MA,CCC-SLP 7100 N High St, 203, Worthington, OH 43085-2316 Ph: (614) 505-7330 | Mrs Sarah Elyse Meyers, MA,CCC-SLP 7100 N High St, 203, Worthington, OH 43085-2316 Ph: (614) 505-7330 |
News Archive
Plexxikon Inc., a member of Daiichi Sankyo Group, today announced that the European Commission has approved Zelboraf (vemurafenib) for the monotherapy treatment of adult patients with BRAFV600 mutation-positive unresectable or metastatic melanoma.
The well-worn notion that patients in the United States have unfettered access to the most expensive cancer drugs while the United Kingdom's nationalized health care system regularly denies access to some high-cost treatments needs rethinking, a team of bioethicists and health policy experts says in a report out today.
With funding from the Biotechnology and Biological Sciences Research Council (BBSRC) neurobiologists from the Institute of Psychiatry and tissue engineers from The University of Nottingham have joined forces to tackle the challenge of tissue loss as a result of stroke.
Early last year, as lawmakers vowed to curb rising drug prices, Sen. Thom Tillis was named chairman of the Senate Judiciary Committee's subcommittee on intellectual property rights, a committee that had not met since 2007.
A study led by researchers at The University of Texas MD Anderson Cancer Center found that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-line therapy for patients with high-risk large B-cell lymphoma (LBCL), a group with an urgent need for new and effective treatments.
› Verified 9 days ago
Kristen Marie Nicol, MA, CCC-SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 7100 N High St Ste 203, Worthington, OH 43085 Phone: 614-505-7330 | |
Olivia Fox, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 445 E Dublin Granville Rd, Worthington, OH 43085 Phone: 614-844-3800 | |
Angela Lynn Bartosic, Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 200 E Wilson Bridge Rd, Worthington, OH 43085 Phone: 614-450-6000 | |
Miss Lisa M Streets, M.S C.C.C SLP Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 200 E Wilson Bridge Rd, Worthington, OH 43085 Phone: 614-450-4900 | |
The Speech Language Path Speech-Language Pathologist Medicare: Not Enrolled in Medicare Practice Location: 7100 N High St Ste 203, Worthington, OH 43085 Phone: 614-505-7330 | |
Bridget O'riordan, Speech-Language Pathologist Medicare: Accepting Medicare Assignments Practice Location: 445 E Dublin Granville Rd, Worthington, OH 43085 Phone: 614-436-7837 |